A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients with Cystic Fibrosis

Project Details

StatusFinished
Effective start/end date1/09/2031/08/21

Funding

  • Novotech (Australia) Pty Limited: AUD22,223.00
  • Novotech (Australia) Pty Limited: AUD47,940.00
  • Novotech (Australia) Pty Limited